Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA512577
Max Phase: Preclinical
Molecular Formula: C10H12N3O9P
Molecular Weight: 349.19
Molecule Type: Small molecule
Associated Items:
ID: ALA512577
Max Phase: Preclinical
Molecular Formula: C10H12N3O9P
Molecular Weight: 349.19
Molecule Type: Small molecule
Associated Items:
Synonyms (2): 6-cyano-UMP | 6-Cyano-Uridine Monophosphate
Synonyms from Alternative Forms(2):
Canonical SMILES: N#Cc1cc(=O)[nH]c(=O)n1[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O
Standard InChI: InChI=1S/C10H12N3O9P/c11-2-4-1-6(14)12-10(17)13(4)9-8(16)7(15)5(22-9)3-21-23(18,19)20/h1,5,7-9,15-16H,3H2,(H,12,14,17)(H2,18,19,20)/t5-,7-,8-,9-/m1/s1
Standard InChI Key: GCVKNFUDFHDSJQ-ZOQUXTDFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 349.19 | Molecular Weight (Monoisotopic): 349.0311 | AlogP: -2.86 | #Rotatable Bonds: 4 |
Polar Surface Area: 195.10 | Molecular Species: ACID | HBA: 9 | HBD: 5 |
#RO5 Violations: 0 | HBA (Lipinski): 12 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 1.23 | CX Basic pKa: | CX LogP: -2.69 | CX LogD: -7.56 |
Aromatic Rings: 1 | Heavy Atoms: 23 | QED Weighted: 0.35 | Np Likeness Score: 0.72 |
1. Poduch E, Bello AM, Tang S, Fujihashi M, Pai EF, Kotra LP.. (2006) Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics., 49 (16): [PMID:16884305] [10.1021/jm060202r] |
2. Bello AM, Poduch E, Liu Y, Wei L, Crandall I, Wang X, Dyanand C, Kain KC, Pai EF, Kotra LP.. (2008) Structure-activity relationships of C6-uridine derivatives targeting plasmodia orotidine monophosphate decarboxylase., 51 (3): [PMID:18189347] [10.1021/jm7010673] |
3. Bello AM, Konforte D, Poduch E, Furlonger C, Wei L, Liu Y, Lewis M, Pai EF, Paige CJ, Kotra LP.. (2009) Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents., 52 (6): [PMID:19260677] [10.1021/jm801224t] |
4. Meza-Avina ME, Wei L, Liu Y, Poduch E, Bello AM, Mishra RK, Pai EF, Kotra LP.. (2010) Structural determinants for the inhibitory ligands of orotidine-5'-monophosphate decarboxylase., 18 (11): [PMID:20452222] [10.1016/j.bmc.2010.04.017] |
Source(1):